If you have been reading about alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Clindamycin/benzoyl peroxide, sold under the brand name Benzaclin among others, is a topical gel used for the treatment of acne. It is a fixed-dose combination of clindamycin, as the phosphate, an antibiotic; and benzoyl peroxide, an antiseptic. Common side effects include peeling, itching, and dryness of the skin where the gel was applied. Clindamycin/benzoyl peroxide was approved for medical use in the United States in December 2000. It is available as a generic medication.
According to The Washington Post, the coalition forces regularly use "torture-like" methods during the interrogation of suspects. Such methods were reportedly applied to people to find the hiding place of Saddam Hussein in Operation Red Dawn. British troops have also on occasion been accused of abusing Iraqi detainees. Such treatment violates article 17 of the Third Geneva Convention and the USA and Britain's official policies on combat and occupation. Despite numerous complaints by Amnesty International and Human Rights Watch, it took a year before the first US soldier was court-martialed for their actions concerning abuse of Iraqis.
4-Fluoro-7-nitrobenzofurazan (NBD-F) is a fluorogenic, amine labeling dye that is not fluorescent itself, but covalently reacts with secondary or primary amines to form a fluorescently labeled product. It and other fluorogenic benzofurans (i.e. NBD-Cl) are used for derivitization in HPLC applications. After the fluorogenic reaction, it can be detected with an excitation wavelength of 470 nm (blue) and an emission wavelength of 530 nm (green), enabling an HPLC limit of detection of 10 fmol.
Like autistic savants, some hyperthymesiacs develop an obsessive fascination with dates. Jill Price, the first documented case, differed notably from mnemonist Solomon Shereshevsky, described by psychologist Alexander Luria. Shereshevsky could deliberately memorise vast amounts of information, whereas Price could recall only autobiographical events and generally performed poorly at memorisation tasks. Hyperthymestic individuals may even have below-average memory for arbitrary information. Another parallel drawn between Price and Shereshevsky is the role of synesthesia. Shereshevsky exemplified time-space synesthesia, and some researchers suggest superior autobiographical memory may be linked to this phenomenon.
Sources: en.wikipedia.org
==== Identification of the formula ==== In the early 1700s, Georg Ernst Stahl claimed that reacting sulfuric acid with limestone produced a sort of alum. The error was soon corrected by Johann Pott and Andreas Marggraf, who showed that the precipitate obtained when an alkali is poured into a solution of alum, namely alumina, is quite different from lime and chalk, and is one of the ingredients in common clay. Marggraf also showed that perfect crystals with properties of alum can be obtained by dissolving alumina in sulfuric acid and adding potash or ammonia to the concentrated solution. In 1767, Torbern Bergman observed the need for potassium or ammonium sulfates to convert aluminium sulfate into alum, while sodium or calcium would not work. At the time, potassium ("potash") was believed to be exclusively found on plants. However, in 1797, Martin Klaproth discovered the presence of potassium in the minerals leucite and lepidolite. Louis Vauquelin then conjectured that potassium was likewise an ingredient in many other minerals. Given Marggraf and Bergman's experiments, he suspected that this alkali constituted an essential ingredient of natural alum. In 1797 he published a dissertation demonstrating that alum is a double salt, composed of sulfuric acid, alumina, and potash. In the same journal volume, Jean-Antoine Chaptal published the analysis of four different kinds of alum, namely, Roman alum, Levant alum, British alum and alum manufactured by himself, confirming Vauquelin's results.
== Structure == Pseudopeptidoglycan is composed of two sugars, N-acetylglucosamine and N-acetyltalosaminuronic acid. These sugars are made of different amino acids, and the peptide cross-links within pseudopeptidoglycan are formed with different amino acids. The peptide bond is formed between the lysine of a N-acetyltalosaminuronic acid and a glutamine of a parallel N-acetyltalosaminuronic acid. Pseudopeptidoglycan, like peptidoglycan in bacteria, forms a mesh-like layer outside of the plasma membrane of the archaea.
α-Haloesters are generally thought of as highly reactive and consequently toxic intermediates in organic synthesis. Nevertheless, mammals, including humans, cats, and rats, appear to biosynthesise traces of an α-bromoester, 2-octyl 4-bromo-3-oxobutanoate, which is found in their cerebrospinal fluid and appears to play a yet unclarified role in inducing REM sleep. Neutrophil myeloperoxidase can use H2O2 and Br− to brominate deoxycytidine, which could result in DNA mutations. Marine organisms are the main source of organobromine compounds, and it is in these organisms that bromine is more firmly shown to be essential. More than 1600 such organobromine compounds were identified by 1999. The most abundant is methyl bromide (CH3Br), of which an estimated 56,000 tonnes is produced by marine algae each year. The essential oil of the Hawaiian alga Asparagopsis taxiformis consists of 80% bromoform. Most of such organobromine compounds in the sea are made by the action of a unique algal enzyme, vanadium bromoperoxidase. The bromide anion is not very toxic: a normal daily intake is 2 to 8 milligrams. However, high levels of bromide chronically impair the membrane of neurons, which progressively impairs neuronal transmission, leading to toxicity, known as bromism. Bromide has an elimination half-life of 9 to 12 days, which can lead to excessive accumulation. Doses of 0.5 to 1 gram per day of bromide can lead to bromism. Historically, the therapeutic dose of bromide is about 3 to 5 grams of bromide, thus explaining why chronic toxicity (bromism) was once so common.
In pharmacokinetics, a loading dose is an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose. A loading dose is most useful for drugs that are eliminated from the body relatively slowly, i.e., which have a long systemic half-life. Such drugs need only a low maintenance dose in order to keep the amount of the drug in the body at the appropriate therapeutic level, but this also means that, without an initial higher dose, it would take a long time for the amount of the drug in the body to reach that level. Drugs which may be started with an initial loading dose include digoxin, teicoplanin, voriconazole, procainamide and fulvestrant. One or a series of doses may be given at the onset of therapy with the aim of achieving the target concentration rapidly.
== See also == Ancient DNA Biocultural anthropology Biological distance analysis Odontometrics Osteoarchaeology Paleopathology Zooarchaeology 2025 in bioarchaeology 2026 in bioarchaeology Dental analysis in archaeology
Sources: en.wikipedia.org
=== Sexual dysfunction and suicidal thoughts associated with Propecia === In 2021, an investigation by Reuters revealed that Merck's baldness drug Propecia (finasteride) caused persistent sexual dysfunction in men. The drug has been linked to over 700 incidences of suicidal thoughts and 110 deaths. Merck has been receiving reports since 1998, but never included the risks on the label. In 2015, Merck was sued by consumer-rights law firm Hagens Berman over a wrongful death linked to Propecia.
Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics. It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound.
Neurological manifestations can include tremors, chorea, myopathy, and in some susceptible individuals (in particular of Asian descent) periodic paralysis. An association between thyroid disease and myasthenia gravis has been recognized. Thyroid disease, in this condition, is autoimmune in nature, and approximately 5% of people with myasthenia gravis also have hyperthyroidism. Myasthenia gravis rarely improves after thyroid treatment and the relationship between the two entities is becoming better understood over the past 15 years.In Graves' disease, ophthalmopathy may cause the eyes to look enlarged because the eye muscles swell and push the eye forward. Sometimes, one or both eyes may bulge. Some have swelling of the front of the neck from an enlarged thyroid gland (a goiter). Minor ocular (eye) signs, which may be present in any type of hyperthyroidism, are eyelid retraction ("stare"), extraocular muscle weakness, and lid-lag. In hyperthyroid stare (Dalrymple sign) the eyelids are retracted upward more than normal (the normal position is at the superior corneoscleral limbus, where the "white" of the eye begins at the upper border of the iris). Extraocular muscle weakness may present with double vision. In lid-lag (von Graefe's sign), when the person tracks an object downward with their eyes, the eyelid fails to follow the downward-moving iris, and the same type of upper globe exposure which is seen with lid retraction occurs, temporarily. These signs disappear with treatment of the hyperthyroidism.
Three more recent reviews reached similar conclusions: little evidence supporting the use of trigger point dry needling to treat upper shoulder pain and dysfunction, evidence not robust enough to draw a clear conclusion about safety and efficacy, and that dry needling for the treatment of myofascial pain syndrome in the lower back appeared to be a useful addition to standard therapies, but stated clear recommendations could not be made because the published studies were small and of low quality. However, a retrospective analysis of 2,910 dry needling interventions as reported by Mabry, et al. identified no reported safety events when dry needling was performed by physical therapists.
A circuit of fluid in the loop of Henle—an important part of the kidneys—allows for gradual buildup of the concentration of urine in the kidneys, by using active transport on the exiting nephrons (tubules carrying liquid in the process of gradually concentrating the urea). The active transport pumps need only to overcome a constant and low gradient of concentration, because of the countercurrent multiplier mechanism. Various substances are passed from the liquid entering the nephrons until exiting the loop (See the nephron flow diagram). The sequence of flow is as follows:
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.